There is a number in the cardiovascular epidemiology of diabetes and smoking that should be more widely known in Indian clinical practice: 6.15. It is the hazard ratio for coronary heart disease mortality in diabetic male smokers compared to non-diabetic, non-smoking men, from a Finnish cohort study that has been replicated in multiple populations. It means that a diabetic man who smokes is more than six times more likely to die from coronary heart disease than a non-diabetic, non-smoking man. Six times. Not 60%. Six times.

This is not a marginal statistical association. It is a compounding of two powerful risk factors — diabetes and smoking — that share biological mechanisms of damage and amplify each other through those shared pathways. And in India, a country where diabetes occurs at younger ages, with higher rates of hypertension comorbidity, and in a population with South Asian-specific cardiovascular susceptibility, the already-extreme risk profile of the diabetic smoker is further compounded.

Smokesafer Gold 5-stage advanced cigarette filters with activated carbon lab-tested reductions 70.2% tar reduction, 71.2% carbon monoxide reduction, and activated carbon filtration. View lab data
The Core Evidence

Zhao et al. (Circulation, AHA, 2015) — the most comprehensive meta-analysis on smoking and mortality in diabetes — pooled 48 cohort studies covering 1.13 million participants with diabetes. Active smoking was associated with RR 1.55 for total mortality and RR 1.49 for cardiovascular mortality in diabetic patients, compared to non-smoking diabetics. A Finnish cohort study found HR 6.15 for coronary heart disease mortality in diabetic male smokers versus non-diabetic, non-smoking males — the compounded comparison that shows what these two risk factors do together, not just independently. For India, with 89 million diabetics, substantial male smoking rates, 70%+ hypertension prevalence in T2DM patients, and South Asian-specific susceptibility to earlier and more severe cardiometabolic disease, this evidence has direct and enormous public health relevance.

HR 6.15
Hazard ratio for coronary heart disease mortality in diabetic male smokers compared to non-diabetic, non-smoking men — the combined effect of two of the most powerful cardiovascular risk factors acting simultaneously
Finnish Cohort Study; cited in Zhao et al. Circulation (2015) meta-analysis

Understanding the Numbers — What HR 6.15 Actually Means

A hazard ratio of 6.15 for coronary heart disease mortality is a very large number in epidemiology. For comparison: having well-controlled hypertension approximately doubles coronary heart disease risk (HR ~2). Having T2DM adds approximately 2–3 fold risk. Smoking adds approximately 2 fold risk in non-diabetics. But when diabetes and smoking combine — the HR for the worst-comparison group (diabetic smokers vs. non-diabetic non-smokers) reaches 6.15 in this study — significantly greater than what would be predicted from multiplying the individual hazard ratios together.

This is the mathematical signature of biological synergy — not mere addition or multiplication, but compounding. The shared mechanisms by which both diabetes and smoking damage the cardiovascular system — endothelial dysfunction, atherosclerosis, platelet aggregation, oxidative stress, inflammation — are being driven by both factors simultaneously, producing cardiovascular damage that accelerates beyond what either factor alone would predict.

Non-diabetic, Non-smoker
1.0×
Reference group — baseline CHD mortality risk
Diabetic, Non-smoker
~2–3×
Diabetes alone significantly elevates CHD risk
Non-diabetic, Smoker
~2×
Smoking alone doubles CHD risk in non-diabetics
Diabetic, Smoker
6.15×
The compounded combination — far beyond what either factor alone predicts
RR 1.55
Higher total mortality in diabetics who smoke vs. non-smoking diabetics — Zhao et al. 2015, 48 studies, 1.13 million participants
Zhao W, et al. Circulation (AHA, 2015)
RR 1.49
Higher cardiovascular mortality in smoking diabetics vs. non-smoking diabetics — the most clinically important comparison for this population
Zhao W, et al. Circulation (AHA, 2015)
89 million
Indians with T2DM — with substantial male smoking rates and 70%+ hypertension co-prevalence, the absolute numbers at extreme risk are very large
IDF Diabetes Atlas 2023; Indian clinical series

Why India Specifically — Five Factors That Make This More Urgent Here

Factor 1: South Asian T2DM Susceptibility — Younger Age, Lower BMI
Indian and broader South Asian populations develop T2DM at younger ages and lower BMI than Western populations — often a decade earlier. This means diabetic Indian male smokers are carrying their compounded cardiovascular risk for longer, in younger arteries that are being exposed to the combined atherogenic burden of hyperglycaemia and tobacco for more cumulative years. The earlier a diabetic smoker accumulates their atherogenic burden, the more cardiovascular damage is present by the time any clinical event occurs.
Factor 2: Hypertension Co-Prevalence — The Triple Threat at Scale
Hypertension is present in over 70% of Indian T2DM patients in clinical series. This makes the "triple threat" of diabetes + smoking + hypertension not a rare subgroup but the dominant clinical profile. Hypertension adds its own cardiovascular risk — and shares mechanisms with both diabetes (endothelial dysfunction, atherosclerosis) and smoking (RAAS activation, mechanical arterial wall stress). The compounding among all three factors in this population creates a cardiovascular risk profile that has no direct parallel in Western evidence bases derived from populations with different comorbidity prevalence patterns.
Factor 3: Bidi Use — Higher Per-Use CO and Tar
A significant proportion of Indian male tobacco users — particularly in lower-income and rural populations — smoke bidis rather than manufactured cigarettes. Bidis are unfiltered, hand-rolled tobacco products that deliver high CO and tar concentrations per use, given their unfiltered character and high puff density. The cardiovascular mechanisms by which smoking damages diabetics — CO-mediated tissue hypoxia, tar-driven atherogenesis, nicotine-driven sympathetic activation — may be more severe per tobacco use episode for bidi smokers than the Western cigarette-derived evidence base suggests. Indian-specific data on bidi use and cardiovascular outcomes in diabetics would be particularly valuable.
Factor 4: The Cessation Infrastructure Gap
As documented in the Kerala RCT, 52% of Indian diabetic tobacco users had never received cessation advice from their doctor. The clinical infrastructure for structured cessation support — counselling services, affordable pharmacotherapy access, follow-up monitoring — remains underdeveloped across much of India. This means that the population most in need of cessation support is also the population least likely to receive it through the healthcare system, creating a compounding public health failure on top of the biological compounding of risk.
Factor 5: Late Diagnosis and Suboptimal Control
Many Indian diabetics are diagnosed late — often when complications are already present — and maintain suboptimal HbA1c control due to medication cost, access barriers, and health literacy gaps. A diabetic smoker with poor glycaemic control (HbA1c above 8%) is carrying all three risk factors — smoking, hyperglycaemia, and frequently hypertension — at maximum intensity simultaneously. The Finnish HR 6.15 was derived from populations with higher healthcare access and better general risk factor management than is typical across India. In poorly controlled Indian diabetic smokers, the actual mortality hazard may be higher still.

"Among patients with diabetes, active smoking was significantly associated with all-cause mortality, cardiovascular mortality, and premature death. The consistent finding across 48 studies is that smoking remains one of the most powerful modifiable risk factors in people with diabetes."

Zhao W, et al., Circulation (AHA, 2015) — 48 cohort studies, 1.13 million participants
Smokesafer Gold 5-stage advanced cigarette filters with activated carbon lab-tested reductions 70.2% tar reduction, 71.2% carbon monoxide reduction, and activated carbon filtration. View lab data

The Mechanisms — Why Diabetes and Smoking Amplify Each Other's Cardiovascular Damage

Both diabetes and smoking damage the cardiovascular system through several shared biological pathways — and when both are active simultaneously, these shared pathways are driven from two independent directions at once.

Endothelial dysfunction: Diabetes damages the endothelium through AGE formation and oxidative stress. Smoking damages it through tar-derived toxic compounds and CO-mediated nitric oxide impairment. Both produce endothelial dysfunction that predisposes to atherosclerotic plaque formation — acting on the same cells through different mechanisms simultaneously.

Atherosclerosis acceleration: Diabetes drives atherogenic dyslipidaemia (small dense LDL, elevated triglycerides, reduced HDL). Smoking does the same — reducing HDL, oxidising LDL, and driving inflammatory plaque formation. Both are hitting the atherosclerotic process simultaneously through independent but convergent pathways.

Thrombosis: Diabetes produces a pro-thrombotic state through platelet hyperactivation, increased fibrinogen, and reduced fibrinolysis. Nicotine independently promotes platelet aggregation and a pro-thrombotic coagulation state. The combination is particularly dangerous at the point of plaque rupture — the event that converts stable atherosclerosis into acute myocardial infarction — where both factors are simultaneously promoting clot formation.

Oxidative stress: Hyperglycaemia generates oxidative stress through multiple pathways (polyol pathway, AGE formation, PKC activation). Cigarette smoke delivers enormous oxidative stress through direct ROS delivery and glutathione depletion. The combined oxidative burden is higher than either alone would produce, and oxidative stress drives every downstream cardiovascular damage mechanism at a faster rate.

For the Indian diabetic male smoker with hypertension: all five of the most powerful independent cardiovascular risk factors are active simultaneously — hyperglycaemia driving endothelial damage and atherosclerosis, smoking driving the same pathways from a different angle, hypertension creating mechanical arterial wall stress, dyslipidaemia (frequently comorbid with T2DM) adding atherogenic substrate, and the South Asian genetic susceptibility to early and severe cardiometabolic disease providing a less-resilient biological baseline. This is the highest-risk cardiovascular profile of any identifiable patient group. Cessation is not one option among many — it is the single most impactful intervention available to this patient.

What Cessation Produces — The Evidence for Cardiovascular Recovery

The Zhao et al. meta-analysis found that former smokers with diabetes had significantly lower cardiovascular mortality than current smokers — confirming that cessation produces meaningful risk reduction even after years of combined exposure. The cardiovascular benefits of cessation in diabetics are well-documented:

Within 20 minutes: blood pressure and heart rate begin to fall. Within 12 hours: blood CO normalises and tissue oxygenation improves. Within weeks: endothelial function begins to recover, platelet aggregability reduces, and the acute pro-thrombotic state begins to resolve. Within 1 year: excess cardiovascular risk attributable to smoking has declined by approximately 50%. Within 5–15 years: cardiovascular mortality risk continues to decline progressively toward that of never-smoking diabetics.

This is a meaningful and achievable recovery. The biological damage of years of combined smoking and diabetes does not vanish overnight — but the ongoing acceleration of that damage stops, and the body's repair mechanisms begin to regain ground. For an Indian diabetic male smoker in his 40s or 50s, cessation now versus continued smoking into the 60s represents a dramatically different cardiovascular trajectory.

For Indian Diabetic Smokers on the Journey Toward Cessation

For Indian diabetic smokers working toward cessation, Smokesafer Gold is an independently tested cigarette filter with lab-verified reductions in the specific compounds most responsible for the cardiovascular damage of smoking in diabetics: 71% CO reduction (addressing tissue hypoxia and CO-mediated cardiac effects), 70% tar reduction (addressing atherogenic and endothelial damage compounds), 67–88% carbonyl reductions (addressing oxidative stress and inflammatory damage), and 47% nicotine reduction (partially addressing sympathetic activation and thrombosis). This is a harm reduction tool — not a cessation therapy and not a substitute for the structured cessation support that every diabetic smoker in India deserves access to. The primary goal remains cessation. View full independent lab data →

Frequently Asked Questions

I have diabetes and I smoke, but my cholesterol is fine and my BP is controlled. Am I still at high risk?
Yes. The cardiovascular mortality elevation in diabetic smokers exists independent of cholesterol levels and blood pressure control. The Zhao et al. meta-analysis confirmed that smoking is an independent risk factor for cardiovascular mortality in diabetics — meaning the excess risk is present even when other factors are managed. Controlled blood pressure and normal cholesterol reduce your risk compared to an uncontrolled patient — but they do not eliminate the independent contribution of smoking to your cardiovascular trajectory.
I am 58 and have been smoking for 30 years. Is it too late to get a cardiovascular benefit from stopping?
No — cessation at any age and any disease stage produces cardiovascular benefit. The Zhao et al. data on former smokers confirms that risk reduction follows cessation even in long-term smokers with established diabetes. The benefit is less than that of a lifelong non-smoker — structural atherosclerotic damage already present does not reverse completely. But the ongoing acceleration of that damage stops, and the risk trajectory bends sharply downward. Cessation at 58 is significantly better than cessation at 65 — which is significantly better than never stopping. The sooner, the more benefit. But there is no age at which cessation ceases to matter.
Should I be getting cardiac screening if I am a diabetic smoker?
Yes. At minimum: ECG (to check for silent ischaemia or conduction abnormalities, which can occur without symptoms in diabetics with autonomic neuropathy); echocardiography if you have breathlessness, oedema, or exercise intolerance; stress testing or CT coronary calcium scoring at your cardiologist's discretion based on your overall risk profile. Discuss with your diabetologist or cardiologist what screening is appropriate for your current risk profile. The elevated cardiovascular mortality data in diabetic smokers makes proactive cardiac assessment, not reactive symptom-based investigation, the appropriate standard of care.
Related Reading on SmokeSafer.in
Why Am I Always Tired With Diabetes? Blood Sugar High Despite Medication Blurry Vision and Diabetes Why Are My Feet Numb? Why Won't My Diabetic Wound Heal? What Smoking Does to a Diabetic's Heart Smoking and Blood Pressure in Diabetics — The Triple Threat How Smoking Damages Kidneys in Diabetics Quitting Smoking With Diabetes — What to Expect What Indian Doctors Say About Smoking and Diabetes

The Bottom Line

Diabetic smokers face cardiovascular mortality that is dramatically higher than non-diabetic non-smokers — not 20% higher, not 50% higher, but 6.15 times higher in the most cited comparison. The Zhao et al. meta-analysis of 48 cohort studies confirms a 55% higher total mortality and 49% higher cardiovascular mortality in smoking diabetics compared to non-smoking diabetics. In India, with 89 million diabetics, substantial smoking rates, high hypertension co-prevalence, South Asian-specific cardiometabolic susceptibility, and a severe cessation infrastructure gap, the public health scale of this excess mortality is enormous.

Cessation reduces this excess risk progressively and significantly. There is no age, diabetes duration, or smoking history at which cessation ceases to produce meaningful cardiovascular benefit. The trajectory can be changed — and the evidence base says how.

The National Tobacco Quitline (1800-11-2356) is free. Your diabetologist can prescribe varenicline or NRT. The Zhao et al. meta-analysis, the Finnish HR 6.15, and the RSSDI 2022 guidelines all point in the same direction. The clinical case for cessation in the Indian diabetic smoker is among the strongest in all of preventive medicine.

More diabetes guides

Continue through the diabetes and smoking series

Structured guides for blood sugar, symptom checks, complications, and practical clinical conversations.

Start here

Can Diabetics Smoke? Does Smoking Increase Blood Sugar? Does Smoking Cause Type 2 Diabetes?Does Bidi Cause Diabetes? Quitting Smoking With Diabetes

Blood sugar and control

Why Smoking Makes Diabetes Harder to Control Smoking and HbA1c Smoking and Insulin Resistance Blood Sugar High Despite Medication

Symptoms

Always Tired With Diabetes Dizzy When Standing With Diabetes Blurry Vision and Diabetes Why Are My Feet Numb? Why Won't My Diabetic Wound Heal?

Organ-specific risks

Carbon Monoxide and Diabetes Smoking and the Diabetic Heart Smoking and Diabetic Kidney Damage Smoking and Diabetic Retinopathy
View all diabetes guides